Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine

Alain Luxembourg, Darron Brown, Celine Bouchard, Anna R. Giuliano, Ole Erik Iversen, Elmar A. Joura, Mary E. Penny, Jaime A. Restrepo, Josefina Romaguera, Roger Maansson, Erin Moeller, Michael Ritter, Joshua Chen

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Our objective was to develop a multivalent prophylactic HPV vaccine that protects against infection and disease caused by HPV16/18 (oncogenic types in existing prophylactic vaccines) plus additional oncogenic types by conducting 3 Phase II studies comparing the immunogenicity (i.e., anti-HPV6/11/16/18 geometric mean titers [GMT]) and safety of 7 vaccine candidates with the licensed quadrivalent HPV6/11/16/18 vaccine (qHPV vaccine) in young women ages 16–26. In the first study (Study 1), subjects received one of 3 dose formulations of an 8-valent HPV6/11/16/18/31/45/52/58 vaccine or qHPV vaccine (control). In Study 2, subjects received one of 3 dose formulations (termed low-, mid-, and high-dose formulations, respectively) of a 9-valent HPV6/11/16/18/31/33/45/52/58 vaccine (9vHPV vaccine) or qHPV vaccine (control). In Study 3, subjects concomitantly received qHPV vaccine plus 5-valent HPV31/33/45/52/58 or qHPV vaccine plus placebo (control). All vaccines were administered at day 1/month 2/month 6. In studies 1 and 3, anti-HPV6/ 11/16/18 GMTs at month 7 were non-inferior in the experimental arms compared with the control arm; however, there was a trend for lower antibody responses for all 4 HPV types. In Study 2, this immune interference was overcome with the mid- and high-dose formulations of the 9vHPV vaccine by increasing antigen and adjuvant doses. In all 3 studies, all vaccine candidates were strongly immunogenic with respect to HPV31/33/45/52/58 and were well tolerated. Based on the totality of the results, the middle dose formulation of the 9vHPV vaccine was selected for Phase III evaluation. Each 0.5mL dose contains 30μg/40μg/60μg/40μg/20μg/20μg/20μg/20μg/20μg of HPV6/11/16/18/31/33/45/52/58 viruslike particles, and 500μg of amorphous aluminum hydroxyphosphate sulfate adjuvant.ClinicalTrials.gov numbers NCT00260039, NCT00543543, and NCT00551187.

Original languageEnglish (US)
Pages (from-to)1313-1322
Number of pages10
JournalHuman vaccines & immunotherapeutics
Volume11
Issue number6
DOIs
StatePublished - Jan 1 2015

Fingerprint

Virus-Like Particle Vaccines
Vaccines
Papillomavirus Vaccines

Keywords

  • Dose selection
  • Formulation
  • HPV
  • Immunogenicity
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine. / Luxembourg, Alain; Brown, Darron; Bouchard, Celine; Giuliano, Anna R.; Iversen, Ole Erik; Joura, Elmar A.; Penny, Mary E.; Restrepo, Jaime A.; Romaguera, Josefina; Maansson, Roger; Moeller, Erin; Ritter, Michael; Chen, Joshua.

In: Human vaccines & immunotherapeutics, Vol. 11, No. 6, 01.01.2015, p. 1313-1322.

Research output: Contribution to journalArticle

Luxembourg, A, Brown, D, Bouchard, C, Giuliano, AR, Iversen, OE, Joura, EA, Penny, ME, Restrepo, JA, Romaguera, J, Maansson, R, Moeller, E, Ritter, M & Chen, J 2015, 'Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine', Human vaccines & immunotherapeutics, vol. 11, no. 6, pp. 1313-1322. https://doi.org/10.1080/21645515.2015.1012010
Luxembourg, Alain ; Brown, Darron ; Bouchard, Celine ; Giuliano, Anna R. ; Iversen, Ole Erik ; Joura, Elmar A. ; Penny, Mary E. ; Restrepo, Jaime A. ; Romaguera, Josefina ; Maansson, Roger ; Moeller, Erin ; Ritter, Michael ; Chen, Joshua. / Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine. In: Human vaccines & immunotherapeutics. 2015 ; Vol. 11, No. 6. pp. 1313-1322.
@article{444a77efb9b14f72a3ce123b217f4986,
title = "Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine",
abstract = "Our objective was to develop a multivalent prophylactic HPV vaccine that protects against infection and disease caused by HPV16/18 (oncogenic types in existing prophylactic vaccines) plus additional oncogenic types by conducting 3 Phase II studies comparing the immunogenicity (i.e., anti-HPV6/11/16/18 geometric mean titers [GMT]) and safety of 7 vaccine candidates with the licensed quadrivalent HPV6/11/16/18 vaccine (qHPV vaccine) in young women ages 16–26. In the first study (Study 1), subjects received one of 3 dose formulations of an 8-valent HPV6/11/16/18/31/45/52/58 vaccine or qHPV vaccine (control). In Study 2, subjects received one of 3 dose formulations (termed low-, mid-, and high-dose formulations, respectively) of a 9-valent HPV6/11/16/18/31/33/45/52/58 vaccine (9vHPV vaccine) or qHPV vaccine (control). In Study 3, subjects concomitantly received qHPV vaccine plus 5-valent HPV31/33/45/52/58 or qHPV vaccine plus placebo (control). All vaccines were administered at day 1/month 2/month 6. In studies 1 and 3, anti-HPV6/ 11/16/18 GMTs at month 7 were non-inferior in the experimental arms compared with the control arm; however, there was a trend for lower antibody responses for all 4 HPV types. In Study 2, this immune interference was overcome with the mid- and high-dose formulations of the 9vHPV vaccine by increasing antigen and adjuvant doses. In all 3 studies, all vaccine candidates were strongly immunogenic with respect to HPV31/33/45/52/58 and were well tolerated. Based on the totality of the results, the middle dose formulation of the 9vHPV vaccine was selected for Phase III evaluation. Each 0.5mL dose contains 30μg/40μg/60μg/40μg/20μg/20μg/20μg/20μg/20μg of HPV6/11/16/18/31/33/45/52/58 viruslike particles, and 500μg of amorphous aluminum hydroxyphosphate sulfate adjuvant.ClinicalTrials.gov numbers NCT00260039, NCT00543543, and NCT00551187.",
keywords = "Dose selection, Formulation, HPV, Immunogenicity, Vaccine",
author = "Alain Luxembourg and Darron Brown and Celine Bouchard and Giuliano, {Anna R.} and Iversen, {Ole Erik} and Joura, {Elmar A.} and Penny, {Mary E.} and Restrepo, {Jaime A.} and Josefina Romaguera and Roger Maansson and Erin Moeller and Michael Ritter and Joshua Chen",
year = "2015",
month = "1",
day = "1",
doi = "10.1080/21645515.2015.1012010",
language = "English (US)",
volume = "11",
pages = "1313--1322",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "6",

}

TY - JOUR

T1 - Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine

AU - Luxembourg, Alain

AU - Brown, Darron

AU - Bouchard, Celine

AU - Giuliano, Anna R.

AU - Iversen, Ole Erik

AU - Joura, Elmar A.

AU - Penny, Mary E.

AU - Restrepo, Jaime A.

AU - Romaguera, Josefina

AU - Maansson, Roger

AU - Moeller, Erin

AU - Ritter, Michael

AU - Chen, Joshua

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Our objective was to develop a multivalent prophylactic HPV vaccine that protects against infection and disease caused by HPV16/18 (oncogenic types in existing prophylactic vaccines) plus additional oncogenic types by conducting 3 Phase II studies comparing the immunogenicity (i.e., anti-HPV6/11/16/18 geometric mean titers [GMT]) and safety of 7 vaccine candidates with the licensed quadrivalent HPV6/11/16/18 vaccine (qHPV vaccine) in young women ages 16–26. In the first study (Study 1), subjects received one of 3 dose formulations of an 8-valent HPV6/11/16/18/31/45/52/58 vaccine or qHPV vaccine (control). In Study 2, subjects received one of 3 dose formulations (termed low-, mid-, and high-dose formulations, respectively) of a 9-valent HPV6/11/16/18/31/33/45/52/58 vaccine (9vHPV vaccine) or qHPV vaccine (control). In Study 3, subjects concomitantly received qHPV vaccine plus 5-valent HPV31/33/45/52/58 or qHPV vaccine plus placebo (control). All vaccines were administered at day 1/month 2/month 6. In studies 1 and 3, anti-HPV6/ 11/16/18 GMTs at month 7 were non-inferior in the experimental arms compared with the control arm; however, there was a trend for lower antibody responses for all 4 HPV types. In Study 2, this immune interference was overcome with the mid- and high-dose formulations of the 9vHPV vaccine by increasing antigen and adjuvant doses. In all 3 studies, all vaccine candidates were strongly immunogenic with respect to HPV31/33/45/52/58 and were well tolerated. Based on the totality of the results, the middle dose formulation of the 9vHPV vaccine was selected for Phase III evaluation. Each 0.5mL dose contains 30μg/40μg/60μg/40μg/20μg/20μg/20μg/20μg/20μg of HPV6/11/16/18/31/33/45/52/58 viruslike particles, and 500μg of amorphous aluminum hydroxyphosphate sulfate adjuvant.ClinicalTrials.gov numbers NCT00260039, NCT00543543, and NCT00551187.

AB - Our objective was to develop a multivalent prophylactic HPV vaccine that protects against infection and disease caused by HPV16/18 (oncogenic types in existing prophylactic vaccines) plus additional oncogenic types by conducting 3 Phase II studies comparing the immunogenicity (i.e., anti-HPV6/11/16/18 geometric mean titers [GMT]) and safety of 7 vaccine candidates with the licensed quadrivalent HPV6/11/16/18 vaccine (qHPV vaccine) in young women ages 16–26. In the first study (Study 1), subjects received one of 3 dose formulations of an 8-valent HPV6/11/16/18/31/45/52/58 vaccine or qHPV vaccine (control). In Study 2, subjects received one of 3 dose formulations (termed low-, mid-, and high-dose formulations, respectively) of a 9-valent HPV6/11/16/18/31/33/45/52/58 vaccine (9vHPV vaccine) or qHPV vaccine (control). In Study 3, subjects concomitantly received qHPV vaccine plus 5-valent HPV31/33/45/52/58 or qHPV vaccine plus placebo (control). All vaccines were administered at day 1/month 2/month 6. In studies 1 and 3, anti-HPV6/ 11/16/18 GMTs at month 7 were non-inferior in the experimental arms compared with the control arm; however, there was a trend for lower antibody responses for all 4 HPV types. In Study 2, this immune interference was overcome with the mid- and high-dose formulations of the 9vHPV vaccine by increasing antigen and adjuvant doses. In all 3 studies, all vaccine candidates were strongly immunogenic with respect to HPV31/33/45/52/58 and were well tolerated. Based on the totality of the results, the middle dose formulation of the 9vHPV vaccine was selected for Phase III evaluation. Each 0.5mL dose contains 30μg/40μg/60μg/40μg/20μg/20μg/20μg/20μg/20μg of HPV6/11/16/18/31/33/45/52/58 viruslike particles, and 500μg of amorphous aluminum hydroxyphosphate sulfate adjuvant.ClinicalTrials.gov numbers NCT00260039, NCT00543543, and NCT00551187.

KW - Dose selection

KW - Formulation

KW - HPV

KW - Immunogenicity

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84940615394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940615394&partnerID=8YFLogxK

U2 - 10.1080/21645515.2015.1012010

DO - 10.1080/21645515.2015.1012010

M3 - Article

C2 - 25912208

AN - SCOPUS:84940615394

VL - 11

SP - 1313

EP - 1322

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 6

ER -